Pangaea Oncology S.A. (PANG)
Market Open
8 Dec, 15:00
XMAD XMAD Primary €
1. 70
0
0%
€
54.47M Market Cap
- P/E Ratio
0% Div Yield
208,800 Volume
- Eps
€ 1.7
Previous Close Day Range
1.7 1.7
Year Range
1.64 1.79
Want to track PANG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PANG trading today higher at €1.7, an increase of 0% from yesterday's close, completing a monthly increase of 0% or €0. Over the past 12 months, PANG stock lost -3.95%.
PANG is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XMAD (EUR).
PANG Chart
Similar
Pangaea Oncology S.A. (PANG) FAQ
What is the stock price today?
The current price is €1.70.
On which exchange is it traded?
Pangaea Oncology S.A. is listed on XMAD.
What is its stock symbol?
The ticker symbol is PANG.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 54.47M.
Has Pangaea Oncology S.A. ever had a stock split?
No, there has never been a stock split.
Pangaea Oncology S.A. Profile
| Professional Services Industry | Industrials Sector | Mr. Javier Rivela-Rodriguez C.F.A., M.B.A. CEO | XMAD Exchange | - ISIN |
| Spain Country | 149 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Pangaea Oncology, S.A. is a prominent medical services company specializing in offering comprehensive services for cancer patients primarily in Spain and other European Union countries. With its foundation in 2006, the company has established a strong foothold in the healthcare sector by providing advanced molecular diagnostic services, conducting clinical trials, and engaging in in vitro drug profiling. Based in Barcelona, Spain, Pangaea Oncology stands at the forefront of cancer care, emphasizing targeted therapy through its innovative diagnostic tools and research capabilities.
Products and Services
- Molecular Diagnostics: Offers an extensive array of tests including mutation analysis in both tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression analysis. These diagnostics play a pivotal role in tailoring cancer treatment to individual patients, enhancing the efficacy of targeted therapies.
- Clinical Trials: Pangaea Oncology conducts clinical trials to evaluate new cancer treatments. By assessing the safety and efficacy of novel therapies, the company contributes to the development of more effective cancer care solutions.
- In Vitro Drug Profiling: Includes MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing. This service supports the identification of potential therapeutic agents by screening drugs in a controlled laboratory environment, simulating their effects on cancer cells.
- Dx Platform: Specializes in companion diagnostic platform validation, comparison against commercially available platforms, and bespoke R&D services for diagnostic companies. The Dx Platform ensures that the diagnostics developed are accurate, reliable, and contribute to personalized treatment plans.
- Biomarker Discovery: Engages in the identification of novel targets for targeted therapies in pre-clinical development. By discovering and validating new biomarkers, Pangaea Oncology aids in the creation of targeted treatments that can improve patient outcomes.
Contact Information
Address: Sabino Arana, 5-19
Phone: 34 93 409 79 81
Website: https://www.panoncology.com
2025 © Marketlog. All Rights Reserved.
